<table>
<thead>
<tr>
<th>Institution</th>
<th>Drug name and approach</th>
<th>Clinical trial location</th>
<th>Source of information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ar. Sapienza University of Rome</td>
<td>Triptetide, oral active peptide rescue agent</td>
<td>Italy</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>AMO Pharma</td>
<td>Tideglusib</td>
<td>USA and UK</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>Osaka University Hospital</td>
<td>Erythromycin (MYD-0124)</td>
<td>Japan</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>Expansion Therapeutics</td>
<td>ERX-963</td>
<td>USA</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>The Scripps Research Institute, University of Florida and Iowa State University</td>
<td>Cugamycin</td>
<td>USA</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>Lupin Pharmaceuticals</td>
<td>Mexiletine</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Harmony Biosciences</td>
<td>Pitolisant</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>University of Florida and Osaka University</td>
<td>Erythromycin and pafuramidine</td>
<td>Japan</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Pompeu Fabra University</td>
<td>Mirtazapine</td>
<td>Spain</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>University of Valencia</td>
<td>Chloroquine</td>
<td>Spain</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Nexien BioPharma</td>
<td>NX04S1, sublingual cannabinoid formulation</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Nexien BioPharma</td>
<td>NX04S2, sublingual cannabinoid formulation</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Arthex Biotech</td>
<td>ARTHEx-01, microRNA small molecule</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Audentes Therapeutics</td>
<td>AT466, AAV-antisense gene therapy</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>NT0200, modular antisense peptide nucleic acid</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Enzerna Biosciences</td>
<td>ENZ-003, artificial site-specific RNA endonucleases gene therapy</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Locana Biosciences</td>
<td>RNA-targeted gene therapy</td>
<td>USA</td>
<td>Funding award</td>
</tr>
<tr>
<td>Avidity Biosciences</td>
<td>Antibody-oligonucleotide conjugate</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Dyne Therapeutics</td>
<td>Antibody-oligonucleotide conjugate</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>University of Newcastle upon Tyne, MDUK Oxford Neuromuscular Centre</td>
<td>Peptide-conjugated oligonucleotide</td>
<td>England</td>
<td>Funding award</td>
</tr>
<tr>
<td>University of Washington</td>
<td>RNAi gene therapy</td>
<td>USA</td>
<td>Conference presentation</td>
</tr>
<tr>
<td>Massachusetts General Hospital and Harvard Medical School</td>
<td>Antisense oligonucleotide</td>
<td>USA</td>
<td>Conference presentation</td>
</tr>
<tr>
<td>University of Illinois at Urbana-Champaign</td>
<td>Small molecule</td>
<td>USA</td>
<td>Funding award</td>
</tr>
<tr>
<td>Genethon</td>
<td>CRISPR-Cas9</td>
<td>France</td>
<td>Publication</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals and CRISPR Therapeutics</td>
<td>CRISPR-Cas9</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>University of Cardiff, University of South Wales, Neuron Therapeutics</td>
<td>SCF1-201, small molecule</td>
<td>UK</td>
<td>Funding award</td>
</tr>
<tr>
<td>AskBio</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Ionis Pharmaceuticals and Biogen</td>
<td>Antisense oligonucleotide</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Triplet Therapeutics</td>
<td>Antisense oligonucleotides and small interfering RNAs</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Syros Pharmaceuticals</td>
<td>Small molecule</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals and Affinia Therapeutics</td>
<td>AAV gene therapy</td>
<td>USA</td>
<td>Press release</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>AskBio</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Genethon</td>
<td>CRISPR-Cas9</td>
<td>France</td>
<td>Publication</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals and CRISPR Therapeutics</td>
<td>CRISPR-Cas9</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>University of Cardiff</td>
<td>SCF1-201, small molecule</td>
<td>UK</td>
<td>Funding award</td>
</tr>
<tr>
<td>AskBio</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Ionis Pharmaceuticals and Biogen</td>
<td>Antisense oligonucleotide</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Triplet Therapeutics</td>
<td>Antisense oligonucleotides and small interfering RNAs</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Syros Pharmaceuticals</td>
<td>Small molecule</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals and Affinia Therapeutics</td>
<td>AAV gene therapy</td>
<td>USA</td>
<td>Press release</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>AskBio</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Genethon</td>
<td>CRISPR-Cas9</td>
<td>France</td>
<td>Publication</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals and CRISPR Therapeutics</td>
<td>CRISPR-Cas9</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>University of Cardiff</td>
<td>SCF1-201, small molecule</td>
<td>UK</td>
<td>Funding award</td>
</tr>
<tr>
<td>AskBio</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Amicus Therapeutics</td>
<td>Gene therapy</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>Ionis Pharmaceuticals and Biogen</td>
<td>Antisense oligonucleotide</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Triplet Therapeutics</td>
<td>Antisense oligonucleotides and small interfering RNAs</td>
<td>USA</td>
<td>Company pipeline</td>
</tr>
<tr>
<td>Syros Pharmaceuticals</td>
<td>Small molecule</td>
<td>USA</td>
<td>Company press release</td>
</tr>
<tr>
<td>NeuBase Therapeutics</td>
<td>Undisclosed</td>
<td>France</td>
<td>Company pipeline</td>
</tr>
</tbody>
</table>

**Notes:**
- Locations of clinical trials are taken from publically available clinical trial registry entries.
- International non-proprietary names or developmental codes are provided in bold.
- We appreciate all those developing new treatment options for DM patients and would be very thankful for any researchers who may have been missed, to update us on your research. Please contact Ben Porter at ben.porter@newcastle.ac.uk

This information is accurate as of 19/05/20.